Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer
- Conditions
- Colorectal Cancer MetastaticColorectal AdenocarcinomaMetastatic Microsatellite Stable Colorectal CarcinomaRefractory Colorectal CarcinomaStage IV Colorectal CancerStage IVA Colorectal CancerStage IVB Colorectal CancerStage IVC Colorectal Cancer
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Emory University
- Target Recruit Count
- 24
- Registration Number
- NCT03800602
- Locations
- 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 426
- Registration Number
- NCT03798080
- Locations
- 🇨🇳
Investigational Site Number 1560054, Changchun, China
🇨🇳Investigational Site Number 1560005, Changchun, China
🇨🇳Investigational Site Number 1560025, Fuzhou, China
Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Lixisenatide (AVE0010)Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010)Drug: Insulin glargine (HOE901)Drug: MetforminDrug: SGLT2 inhibitor
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 878
- Registration Number
- NCT03798054
- Locations
- 🇨🇳
Investigational Site Number 1560013, Shanghai, China
🇨🇳Investigational Site Number 1560004, Shanghai, China
🇨🇳Investigational Site Number 1560029, Shanghai, China
Study of PF 04965842 Effect on MATE1/2K Activity in Healthy Participants
- First Posted Date
- 2019-01-08
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT03796182
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1293
- Registration Number
- NCT03794336
- Locations
- 🇨🇳
CHINA, China, China
The Effect of Calcium and Vitamin D Supplements on Metabolic and Hormonal Disturbances in Polycystic Ovary Syndrome Patients
- Conditions
- Polycystic Ovary SyndromeVitamin D Deficiency/Insufficiency
- Interventions
- First Posted Date
- 2019-01-04
- Last Posted Date
- 2019-06-06
- Lead Sponsor
- Damascus University
- Target Recruit Count
- 40
- Registration Number
- NCT03792984
- Locations
- 🇸🇾
Damascus University of Obstetrics and Gynecology Hospital, Damascus, Syrian Arab Republic
🇸🇾Orient Hospital, Damascus, Syrian Arab Republic
Assessing Goldenseal-drug Interactions Using a Probe Drug Cocktail Approach
- Conditions
- Interaction Drug Food
- Interventions
- Dietary Supplement: goldensealDrug: MetforminDrug: FurosemideDrug: Midazolam oral solutionDrug: Rosuvastatin Oral Tablet
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Washington State University
- Target Recruit Count
- 16
- Registration Number
- NCT03772262
- Locations
- 🇺🇸
Washington State University, Spokane, Washington, United States
Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
- Target Recruit Count
- 150
- Registration Number
- NCT03764605
- Locations
- 🇮🇹
AOUC "Policlinico", Bari, Italy
🇮🇹AOUConsorziale Policlinico Di Bari, Bari, Italy
Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 377
- Registration Number
- NCT03761134
- Locations
- 🇨🇳
Investigational Site Number 1560039, Baotou, China
🇨🇳Investigational Site Number 1560028, Dalian, China
🇨🇳Investigational Site Number 1560040, Baotou, China
A Research Study to Compare Insulin 287 Once a Week to Insulin Glargine (100 Units/mL) Once a Day in People With Type 2 Diabetes.
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Drug: Placebo (insulin 287)Drug: Insulin icodecDrug: MetforminDrug: Dipeptidyl peptidase-4 inhibitorsDrug: Placebo (insulin glargine)Drug: Insulin glargine
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2021-04-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 247
- Registration Number
- NCT03751657
- Locations
- 🇸🇮
Novo Nordisk Investigational Site, Ljubljana, Slovenia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.